The hosts discuss the high cost and highly targeted nature of pharmaceutical ads on news networks, specifically citing Neulasta. Neulasta is used to boost white blood cell counts in chemotherapy patients but carries risks of a fatal ruptured spleen. The segment questions the effectiveness of marketing such specialized drugs directly to the general public.
